Tumor with DNAJB1-PRKACA Fusion
This tumor is characterized by the presence of a specific genetic alteration known as the DNAJB1-PRKACA fusion, which can drive cancer development. It is often associated with liver tumors.
Fibrolamellar Hepatocellular Carcinoma: DNAJB1-PRKACA Vaccine
We are testing a new peptide vaccine for patients with fibrolamellar hepatocellular carcinoma and other tumors with a specific genetic fusion. This study aims to see if it works better when combined with immune checkpoint therapy.
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Fibrolamellar Hepatocellular Carcinoma
Fibrolamellar hepatocellular carcinoma is a rare type of liver cancer that typically occurs in younger individuals and is not associated with chronic liver disease. It often presents with abdominal pain and weight loss.
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Universitaetsklinikum Ulm AöR
Internal Medicine I
Klingenstein, Germany
Universitaetsklinikum Tuebingen
Translational immunology
Tübingen, Germany
Universitaetsklinikum Tuebingen AöR
Kinderheilkunde I
Tübingen, Germany
Sponsor: Universitaetsklinikum Tuebingen
Last updated: Nov 27, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.